# Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

> **NCT02001818** · PHASE2 · COMPLETED · sponsor: **Australasian Leukaemia and Lymphoma Group** · enrollment: 60 (actual)

## Conditions studied

- Chronic Myeloid Leukaemia

## Interventions

- **DRUG:** Nilotinib, Pegylated interferon alpha-2b, Imatinib

## Key facts

- **NCT ID:** NCT02001818
- **Lead sponsor:** Australasian Leukaemia and Lymphoma Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-11
- **Primary completion:** 2022-01-07
- **Final completion:** 2022-01-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02001818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02001818, "Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02001818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*